Instylla
PrivateLast Round
Early Stage
VC
Jul 7, 2025
Est. Valuation
$125.43M
Total Funding Raised
$81.96M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Instylla operates in Healthcare & Life Sciences and is based in Bedford, Massachusetts. Its latest recorded funding round was a Series C round in August 2023.
Instylla is a medical device company that develops liquid embolic solutions for interventional radiology, aimed at providing controlled and effective embolization to enhance patient outcomes.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Instylla Comparables
Compare Instylla with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fluidx Medical Technology | 84% | |
| ABK Biomedical | 81% | |
| Cortex, Inc. | 79% |
For institutional investors. Book with your work email.
Instylla Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Stage VC | Jul 7, 2025 | ||||
| Series C | Aug 15, 2023 | ||||
| Series B | Oct 15, 2020 | ||||
| Debt | Apr 28, 2020 | ||||
| Series A Extension | Jun 12, 2018 | ||||
Series A | Jun 6, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Instylla Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Incept LLC | Series C, Series A, Series B |
| Ascension Ventures | Series C, Series A, Series B |
| CHV | Series C, Series B |
| Incept AI | Series C, Series B |
| Sparta Group LLC | Series C, Series A, Series B |
| Catalyst Health Ventures | Series C, Series A, Series B |
| Excelestar Ventures | Series C, Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 36% MoM, reaching 3.5K.
- Jul 15, 2026
Embrace Hydrogel Embolic System receives FDA approval.
For institutional investors. Book with your work email.
Instylla Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Instylla's valuation, stock price, and market status.
Is Instylla a public or private company?
Instylla is a private company.
What is the current stock price of Instylla?
Instylla is a private company, so its shares have no public market price. Caplight tracks Instylla's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Instylla worth (valuation)?
Instylla's valuation is estimated at $125.4M based on funding round data.
Can I buy Instylla stock?
Instylla shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Instylla's last funding round?
Instylla's most recent funding round was Early Stage VC on July 7, 2025.
Who are the main investors in Instylla?
Key investors in Instylla include CHV, Catalyst Health Ventures, Excelestar Ventures, Delos Capital Partners.
Will Instylla IPO soon?
No public IPO plans have been announced for Instylla.
How can I track Instylla secondary market activity?
Caplight tracks bids, offers, and trades in Instylla's shares on secondary markets.